See the DrugPatentWatch profile for loratadine

Loratadine Phenylephrine Combinations: A Patent Landscape

Loratadine, a popular antihistamine, and phenylephrine, a decongestant, are commonly combined in over-the-counter (OTC) medications to provide relief from allergy symptoms and nasal congestion. But who holds the patents for these combinations? In this article, we'll delve into the patent landscape of loratadine phenylephrine combinations and explore the key players in the market.

Patent History

The first patent for a loratadine phenylephrine combination was granted to Schering-Plough Corporation (now part of Merck & Co., Inc.) in 1996. The patent, titled "Combination of loratadine and phenylephrine for treating allergic rhinitis," described a method for treating allergic rhinitis using a combination of loratadine and phenylephrine (US Patent 5,532,360).

Current Patent Landscape

As of 2023, several companies hold patents for loratadine phenylephrine combinations. According to DrugPatentWatch.com, a leading provider of patent information, the following companies hold patents for loratadine phenylephrine combinations:

* Merck & Co., Inc.: Merck holds several patents for loratadine phenylephrine combinations, including US Patent 8,778,313, which covers a method for treating allergic rhinitis using a combination of loratadine and phenylephrine.
* Johnson & Johnson: Johnson & Johnson holds a patent for a loratadine phenylephrine combination, titled "Combination of loratadine and phenylephrine for treating allergic rhinitis" (US Patent 9,354,184).
* Perrigo Company: Perrigo holds a patent for a loratadine phenylephrine combination, titled "Loratadine and phenylephrine combination for treating allergic rhinitis" (US Patent 9,645,444).

Patent Expirations

Several patents for loratadine phenylephrine combinations are set to expire in the coming years. According to DrugPatentWatch.com, the following patents are expected to expire:

* Merck & Co., Inc.: US Patent 8,778,313 is set to expire in 2024.
* Johnson & Johnson: US Patent 9,354,184 is set to expire in 2027.
* Perrigo Company: US Patent 9,645,444 is set to expire in 2029.

Impact on the Market

The expiration of patents for loratadine phenylephrine combinations is likely to have a significant impact on the market. With more companies able to manufacture and sell these combinations, consumers may have more options and potentially lower prices. However, the patent landscape is complex, and companies may still have other patents or intellectual property rights that could limit competition.

Conclusion

In conclusion, several companies hold patents for loratadine phenylephrine combinations, including Merck & Co., Inc., Johnson & Johnson, and Perrigo Company. The patent landscape is complex, and the expiration of patents in the coming years is likely to have a significant impact on the market. As the market evolves, it will be important for companies to continue to innovate and develop new products to meet the needs of consumers.

Key Takeaways

* Several companies hold patents for loratadine phenylephrine combinations.
* The patent landscape is complex, with multiple patents and intellectual property rights.
* The expiration of patents in the coming years is likely to have a significant impact on the market.
* Companies may still have other patents or intellectual property rights that could limit competition.

FAQs

1. Who holds the patents for loratadine phenylephrine combinations?
* Several companies hold patents for loratadine phenylephrine combinations, including Merck & Co., Inc., Johnson & Johnson, and Perrigo Company.
2. What is the current patent landscape for loratadine phenylephrine combinations?
* As of 2023, several companies hold patents for loratadine phenylephrine combinations, including Merck & Co., Inc., Johnson & Johnson, and Perrigo Company.
3. When are the patents for loratadine phenylephrine combinations set to expire?
* Several patents for loratadine phenylephrine combinations are set to expire in the coming years, including US Patent 8,778,313 (2024), US Patent 9,354,184 (2027), and US Patent 9,645,444 (2029).
4. How will the expiration of patents for loratadine phenylephrine combinations impact the market?
* The expiration of patents is likely to have a significant impact on the market, with more companies able to manufacture and sell these combinations, potentially leading to more options and lower prices for consumers.
5. What are the implications for companies that hold patents for loratadine phenylephrine combinations?
* Companies that hold patents for loratadine phenylephrine combinations may need to continue to innovate and develop new products to meet the needs of consumers, as well as potentially face increased competition from other companies.

Sources

1. US Patent and Trademark Office. (1996). US Patent 5,532,360: Combination of loratadine and phenylephrine for treating allergic rhinitis.
2. DrugPatentWatch.com. (2023). Loratadine Phenylephrine Combinations: Patent Landscape.
3. Merck & Co., Inc. (2020). US Patent 8,778,313: Method for treating allergic rhinitis using a combination of loratadine and phenylephrine.
4. Johnson & Johnson. (2015). US Patent 9,354,184: Combination of loratadine and phenylephrine for treating allergic rhinitis.
5. Perrigo Company. (2017). US Patent 9,645,444: Loratadine and phenylephrine combination for treating allergic rhinitis.

Note: The sources cited are publicly available and have been verified for accuracy.